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Abstract Breast cancer is the most frequent carcinoma and
second most common cause of cancer-related mortality in
postmenopausal women. The acquisition of somatic muta-
tions represents the main mechanism through which cancer
cells overcome physiological cellular signaling pathways
(e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis
and metastasis monitoring is mainly carried out through tissue
biopsy and/or re-biopsy, a very invasive procedure limited
only to certain locations and not always feasible in clinical
practice. In order to improve disease monitoring over time
and to avoid painful procedure such as tissue biopsy, liquid
biopsy may represent a new precious tool. Indeed, it repre-
sents a basin of Bnew generation^ biomarkers that are spread
into the bloodstream from both primary and metastatic sites.
Moreover, elevated concentrations of circulating tumor DNA
(ctDNA) as well as circulating tumor cells (CTCs) have been
found in blood plasma of patients with various tumor types.
Nowadays, several new approaches have been introduced for
the detection and characterization of CTCs and ctDNA,
allowing a real-time monitoring of tumor evolution. This re-
view is focused on the clinical relevance of liquid biopsy in
breast cancer and will provide an update concerning CTCs
and ctDNA utility as a tool for breast cancer patient monitor-
ing during the course of disease.
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Introduction
Breast cancer is the most common carcinoma and one of the
leading causes of cancer-related deaths in women aged be-
tween 35 and 75 years [1, 2]. Although breast cancer seems
to be most often sporadic, about 5–10 % of new cases are
hereditary. Indeed, about half of these would be associated
with germline mutations occurring on codifying DNA se-
quences which determine a high risk of developing the disease
during life and for this reason called Bsusceptibility genes^ [3,
4].
The two major identified susceptibility genes are the tumor
suppressor genes BRCA1 and BRCA2 involved in DNA dou-
ble strand break repair trough the homologous recombination
(HR) pathway. Germline mutations in these genes cause ge-
netic instability that enhance the development of additional
mutations in other pivotal genes involved in cell cycle control
and many others cellular processes [4–7]. Gene expression
profiling studies, performed bymicroarray analysis, highlight-
ed the molecular heterogeneity of breast cancers, allowing the
identification of different molecular subgroups with similar
characteristics. Thus, based on the gene expression profiles,
they were classified into four distinct subtypes: luminal A,
luminal B, human epithelial growth factor receptor 2
(HER2) overexpressing, and basal-like [8]. Furthermore, im-
munohistochemical characterization of the aforementioned
subtypes on the basis of ER, PR, and HER2 expression is
shown in Table 1. Current ESMO guidelines on primary
breast cancer management consider this classification and im-
plement it with Ki-67 levels. The cutoff to distinguish high
from low levels of ki-67 is by 30 % [9]. Histologically, breast
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cancer can be divided into in situ and invasive carcinoma, both
of which can be further subclassified into ductal and lobular
carcinomas [10]. Triple negative breast cancer (TNBC) repre-
sents 15–20 % of all breast cancers. This unfavorable cancer
histotype lacks in the expression of estrogen, progesterone,
and human epidermal growth factor receptor-2 receptors.
Moreover, it usually presents at young age (age <50 years),
advanced stage at first diagnosis, unfavorable outcome, grade
3, high proliferative index, and higher risk of metastases [11,
12].
Even though breast cancer represents the second leading
cause of cancer-related death among women, a significant
proportion of patients can be treated by surgery only or sur-
gery and adjuvant systemic therapies. Despite the improve-
ments in disease management, mortality is still high due to
the emergence of distant metastasis. With the introduction of
new approaches, as well as next-generation sequencing
(NGS), it starts to be clear that clonal evolution occurs, among
a cell population, within the primary tumor and it is mainly
due to intra-tumor heterogeneity [13]. Furthermore, anticancer
therapies may also cause a selective acquisition of new genetic
alterations.
Another relevant drawback in luminal breast cancer is that
the metastatic event can appear years after first diagnosis. This
might be referred as Btumor dormancy,^ it means that cancer
cells may colonize earlier distant sites but stay dormant until
they do not accumulate enough genetic and/or epigenetic
modifications that allow their awakening from Bdormancy^
[14]. Two different possible scenarios can be forecasted for
explaining the metastatic event. According to the first scenar-
io, tumor cells leave the primary site to colonize distant organs
only if they acquire a totally competence to generate a meta-
static development. In the second case, Balmost normal epi-
thelial cells^ leave preneoplastic lesions earlier and evolve
simultaneously with the primary tumor cell population [15].
Currently in the clinical practice, it is very difficult to find a
reliable tool to follow tumor evolution over time, and this lack
is probably the main reason of treatment failure whether ad-
ministered at wrong time points during the course of disease.
Liquid biopsy may represent the solution to the aforemen-
tioned problems. Recent findings demonstrate that circulating
tumor cells (CTCs) and circulating tumor DNA (ctDNA) are
detectable in blood samples even at early stage disease.
Moreover, technological improvements in CTCs and ctDNA
isolation, detection, and analysis are paving the way for their
introduction in the current clinical practice. Moreover, new
insight into the nature and severity of breast cancers could
arise from small extracellular vesicles. Among the extracellu-
lar bodies, the interest of the scientific community in
exosomes biology is daily growing. Indeed, exosomes are
small vesicles (diameter 40–100 nm) involved in mediating
a cross-talk between the extracellular matrix and the cell act-
ing as a shuttle of many compounds as nucleic acids and
proteins [16, 17]. Indeed, these could represent a new intrigu-
ing diagnostic marker because of their possible involvement
in a multitude of cellular processes as well as the event of
tumor growth, metastasis, and not less notable, drug resistance
as effect of anticancer drugs removal from the breast cancer
cells [17, 18].
Few data have been available yet about the assessment
of serum microRNAs in breast cancer as it has been car-
ried out in other malignancies. The development of
microRNA panels in serum would add relevant informa-
tion for breast cancer classification along with messenger
RNA (mRNA) expression levels in tissue and ctDNA
panels in serum [19–22].
The review is focused on the clinical relevance of liquid
biopsy in breast cancer. We will provide an update concerning
CTCs and ctDNA utility as a tool for breast cancer patients
monitoring during the course of disease.
An overview on main signaling pathways involved
in breast cancer
Mutation gain in somatic cells is the pivotal mechanism
through which cancer cells alter normal signaling pathways
[23], in addition to other modifications such as epigenetic
variations which are primarily influenced by the local micro-
environment and germline genetic variations.
Cancer whole-genome studies highlighted a still growing
number of involved somatic mutations, most of which have
not yet a known biological function. The accumulation of
mutations within a cancerous and/or precancerous cell popu-
lation is a dynamic process not fully understood, and until
now, several pathways have been identified as responsible
for the process of mammary carcinogenesis.
The evaluation of estrogen, progesterone, and epidermal
growth factor type 2 receptors (ER, PgR, and HER2, respec-
tively) is widely used in clinical practice in order to obtain
prognostic and predictive information [24]. Also, several other
markers, such as B-cell lymphoma 2, androgen receptor, EGF,
phosphatase and tensin homolog (PTEN), and phos-
phatidylinositol 3-kinase (PI3K), may have prognostic value
in breast cancer. Several studies have reported that mutations
in PI3K are associated with lower recurrence and mortality
Table 1 Immunohistochemical profile of breast cancer subtypes
Luminal A Luminal B HER2+/ER− Basal like
• ER+ • ER+ • ER− • ER−
• and/or PR+ • and/or PR+ • PR− • PR−
• HER2− • HER2+ • HER2+ • HER2−
ER estrogen receptor, PR progesterone receptor,HER2 receptor type 2 for
EGF
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rates [25, 26]. PI3K/Akt/mTOR pathway is often altered in
patients with breast cancer. This pathway controls several bi-
ological activities within the cell, and its activation is one of
the fundamental downstream molecular events following ty-
rosine kinase growth factor receptor activation [27]. The first
event is the activation of PI3K, which, when not inhibited by
PTEN, phosphorylates and activates AKT localizing it in the
plasma membrane [28]. AKT can have a number of down-
stream effects by activating different substrates such as the
mammalian target of rapamycin (mTOR) whose substrate is
S6 Kinase 1 (p70S6K) [29–31] (Fig. 1).
PI3K mutations are more frequent in node-negative (not
spread to nearby lymph nodes), ER-positive, and Her2- neg-
ative patients, and are generally related to a favorable clinical
outcome. Several studies have reported that mutations in PI3K
are associated with lower recurrence and mortality rates [25,
26]. PI3Kmutations are very high recurrent genetic alterations
in breast cancers with a rate of 20–40 % in these cancers [32].
The PI3K/AKT/mTOR pathway plays a central role in regu-
lating cell proliferation, growth, apoptosis, and motility. The
PI3K enzyme is a heterodimer composed of a regulatory (p85)
and a catalytic subunit (p110), and it is activated after the
dimerization and auto-phosphorylation of tyrosine kinase re-
ceptors, such as HER2. Following its activation, PI3K is able
to phosphorylate phosphatydilinositol 4,5-trisphosphate
(PIP2) in phosphatydilinositol 3,4,5-trisphosphate (PIP3) that
is the main actor for the activation of PKB/AKT [33, 34].
Under physiological conditions, the PIP3 levels are tightly
regulated by specific phosphatases, such as PTEN.
Alteration in the PI3K/AKT pathway, due to loss or gain of
expression as well as genetic changes of its members, is a
pivotal event toward a malignant transformation, as already
well described in literature. Several studies have demonstrated
that the gene encoding the PI3K catalytic subunit p110a
(PI3KCA) is mutated in different cancers [35]. Activating
mutations in the p110α catalytic subunit of PI3K has been
also described in 9–45 % of breast cancers [32]. The preferred
mutational Bhot spots^ for PI3KCA are predominantly exons
9 and exon 20; mutations of these exons determine the follow-
ing amino acid substitutions: H1047R, E545K, and E542K.
This mutations account for 70–80 % of PI3KCA alterations in
breast cancer [36]. These hot spot mutations are known to
Fig. 1 Activation mechanism of
PI3K/Akt/mTOR signaling
pathway
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modulate the activity of the PI3K in the signaling pathway
regulating cell growth, motility, and other important cellular
functions [36, 37].
Also, PTEN and AKT are frequently altered in breast can-
cer. As widely highlighted in many forms of infiltrating breast
cancers, PTEN genetic alteration and in particular its loss of
expression yield a probability of incidence quantified in 4–
35 %, while mutations or variations in AKT expression levels
give a percentage of 6 and 15–41 %, respectively. Taken to-
gether, these genetic aberrations seem to play a pivotal role in
the deregulation of PI3K/AKT pathway, and consequently,
this possibly leads to disease progression and therapy resis-
tance [38].
Other relevant mutations in breast carcinogenesis are those
in TP53 gene. Indeed, 83% of basal-like tumors showed TP53
mutations compared to 15 % in the luminal, normal-like, and
HER2-positive tumors [39]. TP53 is a tumor suppressor gene
encoding a 393 amino-acid nuclear phospho-protein whose
role is to arrest propagation of genetically aberrant cells [40].
TP53 mutations also seem to play a role in the epithelial-
mesenchymal transition (EMT) through the inhibition of epi-
thelial markers such as E-cadherin and the transcriptional ac-
tivation of genes associated with a mesenchymal phenotype
such as Twist, ZEB-1, and ZEB-2 [41]. These molecular
events encourage cells to acquire a cancer stem cell-like phe-
notype and to promote tumor growth and metastatic spread.
TP53 expression is also tightly correlated with Ki67 expres-
sion and is negatively associated with histological grade, tu-
mor size, and co-expression of vascular endothelial growth
factor (VEGF), epidermal growth factor receptor (EGFR),
and type II topoisomerase (TOPO II). In addition to the afore-
mentioned genetic alterations, also point mutations, as well as
gene amplification in the ESR1 gene, even though at a low-
frequency, seem to play a role in metastatic breast cancer [32,
42]. Some of these identified mutations seem to lead to ERα
transcriptional activity in a hormone-free manner, promoting
resistance to hormonal treatments [43, 44].
Liquid biopsy
Diagnosis and metastasis monitoring is mostly carried out
through tissue biopsy and re-biopsy, a very invasive tech-
nique, limited, and not easily acceptable by the patients.
In order to obtain an efficient and painless management of
the disease over time, liquid biopsies may represent a precious
basin of Bnew generation^ biomarkers. These biomarkers are
released into the bloodstream from both primary and metasta-
tic sites, and thus, they can provide intriguing information on
tumor evolution. Indeed, elevated concentrations of circulat-
ing nucleic acids have been found in blood plasma or serum of
patients with various tumor types and were often associated
with unfavorable outcome in some clinical studies. These
findings could improve the actual approach to breast cancer
patients and might in the near future help clinicians in modi-
fying the treatment choices according to the tumor evolution.
Circulating tumor DNA: a general overview
Cell-free DNA (cfDNA) was firstly reported in 1948 by
Mandel and Metais in the blood of healthy individuals [45].
Cell-free DNA is a double-stranded nucleic acid with low
molecular weight than genomic DNA that circulate in the
bloodstream in short (between 70 and 200 base pairs in length)
or long fragments up to 21 kb. To date, the source of cfDNA is
still not completely understood, while a big contribute seems
to derive essentially from nucleated blood cells. In cancer
patients, a considerable proportion of cfDNA is thought to
origin from tumor cells although a proportion of fragments
is represented by wild-type DNA as well as in the plasma of
healthy controls. Given that somatic mutation occurs exclu-
sively in tumor cells, the identification of a mutation in
cfDNA can define the portion of circulating tumor DNA
(ctDNA) [46]. The possible reason for the high presence of
nucleic acids into the blood of cancer patients could be ex-
plained as a part of the cell death process (apoptosis and ne-
crosis) in cancer cells. Within the physiological clearance pro-
cess of an apoptotic and/or necrotic cell, macrophages take a
pivotal role in engulfing dead cells and in realizing the
digested DNA into the tissue environment [47]. Another hy-
pothesis is that ctDNA arises from the lysis of circulating
cancer cells or micro metastases, already into the bloodstream,
shed by tumor. The amount of ctDNA that derives from tumor
cells is also affected by specific tumor characteristics, i.e., the
size and the stage of the tumor as well as all the physiological
filtering events triggered into the blood and lymphatic circu-
lation [48].
Circulating tumor DNA levels are considerably lower in
earlier stage disease and consequently more difficult to detect
than in advanced or metastatic disease [49].
Targeted therapies have deeply changed the approaches
to treatment of cancer over the past 10 years. Indeed, al-
most all tumors acquire resistance to systemic treatment as
a result of clonal evolution and selection of resistant cells
within the tumor mass. This Bclonal process^ is tightly
dependent from the heterogeneous characteristic of a tu-
mor. Although genotyping is the most reliable method ap-
plied for classifying tumors for future clinical decisions,
tumor tissues provide only a snapshot and are often diffi-
cult to obtain. Therefore, methods are needed for a rapid,
cost-effective (less-expensive) and noninvasive identifica-
tion of biomarkers at various time points during the course
of disease. Since ctDNA is a potential surrogate for the
entire tumor genome, the use of ctDNA as a liquid biopsy
may represent a valuable tool for obtaining the genetic
follow-up data that are urgently needed.
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Some quantitative study reported differences in terms of
circulating DNA amount between breast cancer and healthy
individuals [50]. Furthermore, the levels of ctDNA in cancer
patients would represent a stable parameter whose fluctuations
during the course of the disease may be correlated with clin-
ical outcome. Indeed, it has been demonstrated that high levels
of ctDNA correlate with tumor size, lymph node involvement,
histopathological grade, and clinical staging [51].
The presence of specific mutations helps to differentiate
ctDNA from normal cfDNA. These somatic mutations, com-
monly single base pair substitutions, are present only in the
genomes of cancer cells and are never present in normal cell
DNA within the same individual. These features confer ele-
vated specific properties to ctDNA as a biomarker. One of the
most common somatic alterations in breast cancer are the mu-
tation in PI3K gene that occurs in 40 % of all breast cancers.
This high mutational frequency renders PI3K a highly inter-
esting circulating biomarker. In a recent study [52], the PI3K
mutations were detected in ctDNA of 13/46 (28 %) patients
with metastatic breast cancer, but no trace of the mutation was
found in patients with resectable breast cancer. These results
suggested that the detection of ctDNA mutations is lower in
the early stage disease compared to more advanced stage and
demonstrated the feasibility of detection of PI3K mutation in
plasma [53].
A more recent study highlighted the utility of ctDNA in the
clinical management of breast cancer patients. The study of
Dawson et al., conducted on 30 women with metastatic dis-
ease under chemotherapy, compared the radiographic mea-
surement of tumors with the molecular analysis of ctDNA as
well as CA 15–3 and circulating tumor cells. With respect to
CA15-3 and CTCs which showed not high detectability with-
in the sample, ctDNAwas identified in almost all 30 patients
(29/30) in whom mutations of TP53 and PI3K were already
characterized in tumor biopsy specimens. This assay proved
the high sensitivity of ctDNA for detecting presence of meta-
static disease and study tumor burden when compared to the
aforementioned biomarkers. Furthermore, the researchers
found that ctDNA levels are often associated with both treat-
ment efficacy and survival. In fact, patient with longer surviv-
al showed lower ctDNA levels if compared with patients who
showed early disease progression and shorter survival [54,
55].
Technical approaches for ctDNA
Nowadays, circulating tumor DNA represent a very high chal-
lenging and innovative analyte. Because of its very low con-
centration and degree of fragmentation in liquid samples, it
needs very sensitive detection methods. Moreover, it has been
demonstrated that plasma represents a better ctDNA source
than serum, although the amount of ctDNA in serum can be
2–24 times higher than in plasma [56]. Indeed, during the
ctDNA isolation process, it exists a high risk of cell contam-
ination, and for this reason, it has been recommended the use
of plasma as a source for the analysis of tumor-specific DNA.
Moreover, another benefit deriving from plasma ctDNA is the
lower concentration of background wild-type DNA [57]. One
of the main issues in ctDNA analysis is the assay specificity
and sensitivity. In fact, a major drawback of the ctDNA assays
is the low frequency of some mutations that occur in tumors
and the risk of interference bywild-type sequences [58]. There
are now many methods for assessing ctDNA including the
following:
& BEAMing a technology which combines emulsion PCR
with magnetic beads and flow cytometry for the highly
sensitive detection and quantification of tumor DNA
molecules
& Next-generation sequencing approaches
& Digital PCR platforms
Each technique is able to detect mutant alleles with a sen-
sitivity of at least 2 %. Unfortunately, costs and feasibility of
developing the aforementioned methods in the clinic practice
show several technical issues. However, the use of these strat-
egies would allow and help clinicians in monitoring the dis-
ease progression by quantifying the number of ctDNA copies
per milliliter of plasma (copies/mL) [59].
Circulating tumor DNA: applications
The application of new sensitive methods for very rare circu-
lating mutation is urgently needed. In fact, the feasibility and
potential utility of ctDNA for detection of PI3K mutations
have been already deeply highlighted in patients with meta-
static breast cancer [53, 60].
Recently, the detection of tumor DNA from tissue speci-
mens and paired plasma samples has been reported.
Moreover, the possibility to find mutations in ctDNA at early
stage breast cancer can acquire high value as a marker for
Bminimal residual disease^ (MRD) in those patients subjected
to curative surgery. In particular, a recent work published by
the group of Beaver et al. [61] investigated PI3K exon 20 and
exon 9mutational status through droplet digital PCR (ddPCR)
in both tissue and paired plasma samples. The ddPCR is a
new, highly sensitive, and cost-effective method that allows
the analysis of rare mutation in a background of thousands of
wild-type molecules. The aim of this study was to provide a
proof-of-concept on the potential role of ctDNA as a marker
for MRD. Nowadays, breast surgery represents the elective
treatment for localized breast cancer patients. Unfortunately,
to date, we do not have any marker to recognize patients
definitively cured from those who may still have residual dis-
ease and thus may benefit from adjuvant treatment [46].
Beaver et al. [61] have analyzed 29 presurgery plasma
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samples and compared the results obtained with paired post-
surgery samples with the aim to highlight differences in PI3K
fraction abundance among samples before and after resection.
They showed that PI3K (exons 9 and 20) mutation levels in
plasma differ among pre- and post-surgery withdrawal. These
results, although preliminary, are very intriguing and could
lead to a more personalized breast cancer management [61].
The feasibility of ctDNA analysis have been, not so far,
investigated by Higgins et al., by using a BEAMing approach.
This analysis was conducted within a double, retrospective
and prospective, cohort of metastatic breast cancer patients.
In the retrospective study, the aim was to verify BEAMing
feasibility for the detection of PI3KCA mutations in plasma
that was present in paired tumor tissue specimens. Themethod
resulted reliable in identifying the same mutations observed in
FFPE-derived tissue samples with a concordance of 100 %. In
the prospective analysis, a cohort of 51 metastatic breast can-
cers was studied for PIK3CA mutations both by sequencing
and BEAMing in tumor tissue and paired ctDNA. Also for
this cohort, a high concordance rate was highlighted [62].
Another interesting molecular marker is TP53 mutation
that can be evaluated from ctDNA as well as PI3K mutations.
In particular, Madic et al. have demonstrated that TP53 muta-
tions in plasmamay help in the management of triple-negative
breast cancer patients [63]. Mutations within TP53 sequence
were analyzed by using next-generation sequencing plat-
forms. TAm-Seq-based Illumina and 454 sequencing success-
fully allowed TP53mutation detection in 84% of tumor tissue
specimens. The double NGS approach confirmed the same
genetic alteration also in the paired plasma in 81 % of cases,
demonstrating the robustness of NGS as a method to detect
TP53 mutations [63].
CTCs: a general overview
Circulating tumor cells (CTCs)were first observed in the nine-
teenth century [64, 65]. Generally, CTCs have peculiar fea-
tures including a visible nucleus and cytoplasm, and are main-
ly characterized for the expression of cytokeratin and no
CD45 expression [66].
Since CTCs do not circulate in healthy patients and
have been detected in patients with almost all cancer
types, they acquire high relevance for studying the biology
of the early metastatic disease and for diagnosis of meta-
static patients [67].
Circulating tumor cells show a very low frequency in
bloodstream [68]. Indeed, the number of CTCs would provide
real-time information on the clinical behavior of many tumors,
and they could additionally predict clinical outcome in meta-
static patients [69, 70] as they seem to play a crucial role in
mediating metastatic spread [71].
In fact, metastasis is a multistep process starting with the
detachment of high malignant potential cells from the primary
tumor site that could flow in bloodstream or the lymphatic
system, and reach new distant sites. The final step for a circu-
lating tumor cell is to extravasate, implant, and then proliferate
generating a macroscopic, clinically detectable neoplastic
growths [72].
Since CTCs seem to play crucial roles not only in metasta-
sis but also in resistance to drug administration, it is funda-
mental to understand their clinical role during the early stages
of the disease [73, 74].
Indeed, CTCs can predict early recurrence as well as de-
creased overall survival in chemo-naive patients with
nonmetastatic breast cancer. These results confirm that the
assessment of CTC might provide important prognostic infor-
mation in these patients [75].
In a work by Franken et al. [76], a correlation study be-
tween stage and CTCs number was reported. The CTCs num-
ber evaluation was carried out using three cohorts of patients
in stages I, II, and III, respectively. The detection of ≥1 CTCs
in bloodstream was 16 % for breast cancer patients at stage I,
18 % for stage II, and 31 % for stage III. Therefore, CTC
number positively correlates to disease stage, and patients
with at least one CTC detected showed higher risk of recur-
rence than patients with no CTC detected. Furthermore, CTC
evaluation before surgery plays a pivotal role in predicting
disease-free survival (DFS) [76].
Furthermore, a massive presence correlates more
strongly with poor prognosis than single CTCs in meta-
static breast cancer patients [77]. On the basis of the dif-
ferent degree of epithelial and/or mesenchymal marker
expression, CTCs can be divided different subpopulations
[78, 79]. These subpopulations may also acquire general
cancer stem-like properties allowing them to act as not
differentiated cells by regulating several biological pro-
cesses as quiescence, self-renewal, asymmetric division,
drug resistance, resistance to radiation, and abilities in
surviving within a foreign microenvironment, resulting
then in metastasis. In fact, these stem-like breast cells
commonly show a CD44+/CD24− phenotype [80] or the
expression of aldehyde dehydrogenase 1 (ALDH1) [81].
Technical approaches for CTCs
CTCs are high malignant cells that circulate in bloodstream
at extremely low frequency. CTC number is even lower in
nonmetastatic disease [82, 83]. Current technical ap-
proaches for detecting CTCs can be mainly classified in
enrichment and detection steps on the basis of specific
capture properties (Fig. 2). Through enrichment methods,
CTCs are detected for their physical properties such as cell
size, density, and positive or negative immunoselection. In
fact, CTCs are 20–30 μm in diameter, while blood cells
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measure 8–12 μm [84]. Indeed, in order to discriminate
cells for their size, several filtration methods have been
developed [85]. Mononuclear cells and CTCs can also be
discriminated from other cells on the basis of their density
by performing a ficoll-gradient enrichment [86]. However,
the most commonly used techniques for CTCs enrichment
are the immuno-based approaches. The only FDA- ap-
proved automatized immunomagnetic enrichment is the
CellSearch system. It relies on the ability of magnetic
ferrofluids coupled to anti-EpCAM antibodies to recognize
and bind only epithelial tumor cells expressing EpCAM,
indirectly discriminating them from blood cells. Anti-
EpCAM antibodies are added to 7.5 mL of peripheral
whole blood [51]. EpCAM and members of the CKs family
(CK8, CK18, and CK19) have been identified as useful
markers for positive discrimination in patients with carci-
noma. In particular, positive markers for breast cancer en-
richment are considered EpCAM/CK, HER-2, Mammag
lobin, and MUC-1 for their high expression degree in can-
cer cells [87]. On the contrary, negative discrimination can
be carried out by using antigens as CD45, expressed in
leukocytes, and CD61, expressed in megakaryocytes and
platelets [88].
On the other hand, methods of CTC detection are divided
into the following:
1. Nucleic-acid-based approaches: it relies on specific DNA
or mRNA markers useful to identify and discriminate
CTCs as epithelial-specific genes (CK and EpCAM),
organ-specific markers (CEA, PSA [89], mammaglobin
[90], and MUC-1 [91]) and tumor-specific markers such
as the EGFR andHER-2 genes which are normally absent
in circulation [92].
2. Immunology-based assay: it represents an effective meth-
od for CTCs detection and isolation. It uses labeled anti-
bodies against epithelial or tumor-associated antigens
along with automated digital microscopy or flow cytom-
etry to identify and quantify CTCs.
3. Epithelial immunospot (EPISPOT) assay: it allows the
detection of tumor-specific proteins.
Circulating tumor cells: applications
CTCs represent a reliable therapeutic indicator for many
forms of cancer as indicated in recent evidences that sug-
gested a strong correlation between CTC number and out-
come with respect to PFS and OS [93, 94]. Many clinical
trials have been specifically drawn to demonstrate that
CTC identification and characterization may be used for
improving the management of breast cancer patients as
well for patients’ stratification. Indeed, metastatic breast
cancer patients showing a ≥5 CTCs number after 3–
5 weeks from systemic and hormone- therapies correlate
with shorter PFS than patients with less than five CTCs.
Moreover, this strong correlation has been also demon-
strated between CTCs counts and radiographic disease
progression in patients treated with chemotherapies and
hormone therapies [95]. Therefore, CTC isolation could
be used in addition to standard methods for monitoring
disease status in metastatic breast cancer [96]. A few stud-
ies suggest that CTC number may have a potential prog-
nostic role in early-stage patients. Indeed, CTCs are de-
tectable in 20–40 % of patients with early-stage breast
cancer according to the aforementioned PCR-based assays
and almost 10 % of early-stage patients according to the
CellSearch system [93, 94, 97]. With respect to the main
genetic alteration involved in breast carcinogenesis,
Fernandez et al. [98] showed the feasibility of using
CTCs for TP53 mutation detection as a noninvasive meth-
od. In particular, CTCs from two triple negative breast
cancer patients were enriched using CellSearch system
and single cell selected by DEPArray™. Distinct CTC
populations were found, some of which harboring the
same TP53 mutation (R110 delG), and also confirmed in
the paired tumor samples, while some other showed either
a different TP53 mutation (TP53 R110 delC) or the wild-
type allele. These results indicate that CTCs could repre-
sent a noninvasive source of cancer cells for the determi-
nation of disease progression and the identification of new
potential therapeutic targets [98].
Methods for detecting CTCs 
Enrichment Detection
Cell size
Density
+/- Immunoselection
Phisical Properties
Nucleic-acid 
based 
approaches 
Immunology-
based assay 
Epithelial 
immunospot
assay
Fig. 2 Main technical approaches for CTCs isolation and enrichment
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Conclusions
In the last few years, we have experienced an increased
interest of genetic aberration role in carcinogenesis. In
fact, the use of molecular biomarkers in the next future
would probably help clinicians in evolving their actual
approach to patients’ management for different forms of
cancer (i.e., c-KIT and PDGFRA in GIST, EGFR in lung
cancer, BRAF in melanoma, RAS in colorectal cancer,
PTEN and TP53 in breast cancer). Moreover, the intro-
duction in clinical practice of many new generation ap-
proaches is day-by-day increasing the spectrum of gene
mutations whose involvement in cancer would drive on-
cologist to new personalized treatments delivering.
Despite this wide range of new acquired knowledge, mor-
tality rate is still high. This is mainly caused by the de-
velopment of metastasis due to cancer cell detachment
from the primary tumors. It is now widely demonstrated
that metastasis and primary tumors are biologically differ-
ent. Therefore, these heterogeneity characteristics give to
the metastatic disease the reason for considering it as a
world apart to be still completely discovered. Thus, char-
acterizing new lesions through a re-biopsy appears to be
fundamental. Unfortunately, re-biopsy is not always indi-
cated due to many reasons, first of all the extreme inva-
siveness that limits the procedure only to certain loca-
tions. In order to overcome these issues, the possibility
of using liquid biopsies plays a primary role. CTCs and
ctDNA have been well characterized as useful new and
noninvasive biomarkers that can be used routinely be-
cause of their ease of access within many body fluids.
Circulating tumor DNA is a double-stranded nucleic acid
with low molecular weight that has been detected in the
plasma and serum of cancer patients as well as in that of
healthy controls. In cancer patients a considerable propor-
tion of plasma DNA seems to originate from tumor cells,
although another amount seem to derive from circulating
cancer cells lysis as well as micro metastases. Moreover,
ctDNA amount strongly correlates with tumor stage and
size. The use of ctDNA as a liquid biopsy may help to
obtain the genetic follow-up data that are urgently needed.
Regarding CTCs analysis, at present, their role can be
mainly limited to prognostic purposes, but there is an
increasing interest in the development of new techniques
for their molecular characterization. CTCs are cells that
escape from the primary tumors and migrate through the
circulation until they colonize a new district. It is well-
known from recent clinical studies that their count is pro-
portional to a poorer prognosis in various tumor types.
Following this consideration, the growing interest in the
last few years by the scientific community to liquid biop-
sies gives hope for their routinely application in clinic
practice. Even if the road seems to be long and winding,
new efforts and investments are needed to bridge the gap
still existing.
Compliance with ethical guidelines
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